Rosetta Inks Commercialization Deal for miRNA Tests with Genetic Technologies

Under the arrangement, Genetic Technologies will hold the market rights to the three tests in Australia, New Zealand, and Singapore.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.